title: Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma.
abstract: BACKGROUND
  Excellent results after resection of colorectal liver metastases are associated with a high rate of recurrence. Influenced by positive results of palliative and adjuvant treatment in advanced cancer, various chemotherapy regimens were evaluated to improve long-term results.
  
  
  METHODS
  The databases Medline and Cancerlit (1982-1998) gave information about 675 patients who were treated either by means of systemic, intra-arterial, intraportal or intraperitoneal administration before or after liver resection.
  
  
  RESULTS
  In general, the feasibility of an adjuvant treatment was tested. Proof has been furnished for the practicability of systemic and arterial therapy and for immunotherapy after liver resection whereas, for peritoneal and portal treatment, further studies are necessary. In a few non-randomised trials, it has been possible to discern a trend towards an improvement due to adjuvant postoperative therapy using historical or matched-pair control groups. Until now, only one of five randomised studies has been published. Six months of postoperative adjuvant intra-arterial treatment using 5-fluorouracil (1000 mg/m(2) for 5 days every 28 days) and folinic acid (200 mg/m(2) for 5 days every 28 days) was compared with observation only. Neither in the intention-to-treat nor in the as-treated analysis was median survival time (34.5 months versus 40. 8 months and 39.7 months versus 44.8 months, respectively) significantly increased. As neoadjuvant treatment was successful in primary non-resectable patients, this approach is now being tested in resectable patients.
  
  
  CONCLUSIONS
  Despite several theoretical reasons for post- or preoperative treatment in resectable patients, every approach should be tested using of controlled studies.
authors.affiliation: Department of General and Vascular Surgery, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, D-60590, Frankfurt, Germany,
authors.forename: M
authors.initials: M
authors.lastname: Lorenz
authors.forename: H H
authors.initials: HH
authors.lastname: Müller
authors.forename: E
authors.initials: E
authors.lastname: Staib-Sebler
authors.forename: G
authors.initials: G
authors.lastname: Vetter
authors.forename: C
authors.initials: C
authors.lastname: Gog
authors.forename: H
authors.initials: H
authors.lastname: Petrowsky
authors.forename: C H
authors.initials: CH
authors.lastname: Köhne
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000473:pathology*; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local
chemical_list: D000970:Antineoplastic Agents